A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

被引：0
|
作者：
Jacqueline E. Paramarta
Maureen C. Turina
Troy Noordenbos
Tanja F. Heijda
Iris C. Blijdorp
Nataliya Yeremenko
Dominique Baeten
机构：
[1] Academic Medical Center/University of Amsterdam,Department of Clinical Immunology and Rheumatology
[2] Academic Medical Center/University of Amsterdam,Laboratory of Experimental Immunology
来源：
Journal of Translational Medicine | / 14卷
关键词：
Spondyloarthritis; Nilotinib; Tyrosine kinase inhibitor; Randomized controlled trial; Mast cells;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
    Paramarta, Jacqueline E.
    Turina, Maureen C.
    Noordenbos, Troy
    Heijda, Tanja F.
    Blijdorp, Iris C.
    Yeremenko, Nataliya
    Baeten, Dominique
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [2] TARGETING SYNOVIAL MAST CELLS IN SPONDYLOARTHRITIS: A PROOF-OF-CONCEPT STUDY WITH NILOTINIB A TYROSINE KINASE INHIBITOR
    Paramarta, J. E.
    Turina, M. C.
    Noordenbos, T.
    Heijda, T. F.
    Blijdorp, I. C.
    Yeremenko, N.
    Baeten, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 120 - 121
  • [3] TARGETING SYNOVIAL MAST CELLS IN SPONDYLOARTHRITIS: A PROOF-OF-CONCEPT STUDY WITH THE TYROSINE KINASE INHIBITOR NILOTINIB
    Paramarta, J. E.
    Turina, M. C.
    Heijda, T. F.
    Blijdorp, I. C.
    Noordenbos, T.
    Yeremenko, N.
    Baeten, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 774 - 774
  • [4] Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib.
    Paramarta, Jacqueline E.
    Turina, Maureen C.
    Heijda, Tanja F.
    Blijdorp, Iris C.
    Noordenbos, Troy
    Yeremenko, Nataliya
    Baeten, Dominique L.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375
  • [5] Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts
    Maksymowych, Walter P.
    LANCET RHEUMATOLOGY, 2024, 6 (08): : e498 - e500
  • [6] Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor
    Blay, Jean-Yves
    von Mehren, Margaret
    SEMINARS IN ONCOLOGY, 2011, 38 (02) : S3 - S9
  • [7] The skeletal effects of the tyrosine kinase inhibitor nilotinib
    O'Sullivan, Susannah
    Lin, Jian-Ming
    Watson, Maureen
    Callon, Karen
    Tong, Pak Cheung
    Naot, Dorit
    Horne, Anne
    Aati, Opetaia
    Porteous, Fran
    Gamble, Greg
    Cornish, Jillian
    Browett, Peter
    Grey, Andrew
    BONE, 2011, 49 (02) : 281 - 289
  • [8] Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
    Gordon, Jessica
    Spiera, Robert
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011
  • [9] The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state
    Alhawiti, Naif
    Burbury, Kate L.
    Kwa, Faith A.
    O'Malley, Cindy J.
    Shuttleworth, Peter
    Alzard, Mohamad
    Hamadi, Abdullah
    Grigg, Andrew P.
    Jackson, Denise E.
    THROMBOSIS RESEARCH, 2016, 145 : 54 - 64
  • [10] The skeletal effects of the tyrosine kinase inhibitor nilotinib Reply
    O'Sullivan, Susannah
    Grey, Andrew
    BONE, 2011, 49 (05) : 1119 - 1119
12345